The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
Open accessAbstract
Prostaglandins (PG) are synthesized by two isoforms of the enzyme PG G/H synthase [cyclooxygenase (COX)]. To examine selectivity of tolerated doses of an inhibitor of the inducible COX-2 in humans, we examined the effects of celecoxib on indices of COX-1-dependent platelet thromboxane (Tx) A 2 and on systemic biosynthesis of prostacyclin in vivo . Volunteers received doses of 100, 400, or 800 mg of celecoxib or 800 mg of a nonselective inhibitor, ibuprofen. Ibuprofen, but not celecoxib, significantly inhibited TxA 2 -dependent aggregation, induced ex vivo by arachidonic acid (83 ± 11% vs. 11.9 ± 2.2%; P < 0.005) and by collagen. Neither agent altered aggregation induced by thromboxane mimetic, U46619. Ibuprofen reduced serum TxB 2 (−95 ± 2% vs. −6.9 ± 4.2%; P < 0.001) and urinary excretion of the major Tx metabolite, 11-dehydro TxB 2 (−70 ± 9.9% vs. −20.3 ± 5.3%; P < 0.05) when compared with placebo. Despite a failure to suppress TxA 2 -dependant platelet aggregation, celecoxib had a modest but significant inhibitory effect on serum TxB 2 4 hr after dosing. By contrast, both ibuprofen and celecoxib suppressed a biochemical index of COX-2 activity (endotoxin induced PGE 2 in whole blood ex vivo ) to a comparable degree (−93.3 ± 2% vs. −83 ± 6.1%). There was no significant difference between the doses of celecoxib on COX-2 inhibition. Celecoxib and ibuprofen suppressed urinary excretion of the prostacyclin metabolite 2,3 dinor 6-keto PGF 1α . These data suggest that ( i ) platelet COX-1-dependent aggregation is not inhibited by up to 800 mg of celecoxib; ( ii ) comparable COX-2 inhibition is attained by celecoxib (100–800 mg) and ibuprofen (800 mg) after acute dosing; and ( iii ) COX-2 is a major source of systemic prostacyclin biosynthesis in healthy humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.
Hamberg, M., Svensson, J., & Samuelsson, B. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.2994 · Cited by 3,045
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90246-1 · Cited by 2,514
Tsujii, M., & DuBois, R. N. (1995) · Cell · doi:10.1016/0092-8674(95)90127-2 · Cited by 2,267
Penning, T. D., Talley, J. J., Bertenshaw, S. R., Carter, J. S., Collins, P. W., Docter, S., Graneto, M. J., Lee, L. F., Malecha, J. W., Miyashiro, J. M., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm960803q · Cited by 1,965
Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents
Kurumbail, R. G., Stevens, A. M., Gierse, J. K., McDonald, J. J., Stegeman, R. A., Pak, J. Y., Gildehaus, D., iyashiro, J. M., Penning, T. D., Seibert, K., et al. (1996) · Nature · doi:10.1038/384644a0 · Cited by 1,917
Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L., & Simmons, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2692 · Cited by 1,707
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Seibert, K., Zhang, Y., Leahy, K., Hauser, S., Masferrer, J., Perkins, W., Lee, L., & Isakson, P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12013 · Cited by 1,551
Hla, T., & Neilson, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7384 · Cited by 1,465
Cited by
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Self-citationSilverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., et al. (2000) · JAMA · doi:10.1001/jama.284.10.1247 · Cited by 3,154
Cyclooxygenases: Structural, cellular, and molecular biology
Smith, W. L., DeWitt, D. L., & Garavito, R. M. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.145 · Cited by 2,925
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Platelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs
Wolfe, M. M., Lichtenstein, D. R., & Singh, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199906173402407 · Cited by 1,956
Risk of Cardiovascular Events Associated with Selective COX-2 Inhibitors
Mukherjee, D. (2001) · JAMA · doi:10.1001/jama.286.8.954 · Cited by 1,741
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
Simmons, D. L., Botting, R. M., & Hla, T. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.3 · Cited by 1,693
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
Self-citationThun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets
Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I., & Wang, D. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00443-w · Cited by 1,414
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., & FitzGerald, G. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003199 · Cited by 1,394
Self-citationLow-Dose Aspirin for the Prevention of Atherothrombosis
Patrono, C., García Rodríguez, L. A., Landolfi, R., & Baigent, C. (2005) · New England Journal of Medicine · doi:10.1056/nejmra052717 · Cited by 1,218
Grosser, T. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27291 · Cited by 1,027
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Self-citationWang, D. (2006) · Gut · doi:10.1136/gut.2004.047100 · Cited by 899
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
The Endothelium and Its Role in Regulating Vascular Tone
Sandoo, A., Veldhuijzen van Zanten, J. J. C. S., Metsios, G. S., Carroll, D., & Kitas, G. D. (2010) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401004010302 · Cited by 814
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A 2
Cheng, Y., Austin, S. C., Rocca, B., Koller, B. H., Coffman, T. M., Grosser, T., Lawson, J. A., & FitzGerald, G. A. (2002) · Science · doi:10.1126/science.1068711 · Cited by 789
Self-citationRao, P., & Knaus, E. E. (2008) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t886 · Cited by 773
Patrono, C., Baigent, C., Hirsh, J., & Roth, G. (2008) · Chest · doi:10.1378/chest.08-0672 · Cited by 748
NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2
Wallace, J. L., McKnight, W., Reuter, B. K., & Vergnolle, N. (2000) · Gastroenterology · doi:10.1053/gast.2000.16510 · Cited by 705
Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects
Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., & Roth, G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.234s · Cited by 671
Self-citationGoldstein, J. L., Eisen, G. M., Lewis, B., Gralnek, I. M., Zlotnick, S., & Fort, J. G. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00619-6 · Cited by 659
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
Warner, T. D., & Mitchell, J. A. (2004) · The FASEB Journal · doi:10.1096/fj.03-0645rev · Cited by 614
Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis?
Van Doornum, S., McColl, G., & Wicks, I. P. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10089 · Cited by 606
Diclofenac: an update on its mechanism of action and safety profile
Gan, T. J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.486301 · Cited by 600
Genetic and pharmacological analysis of prostanoid receptor function
Narumiya, S., & FitzGerald, G. A. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13455 · Cited by 568
Self-citationStructural and Functional Basis of Cyclooxygenase Inhibition
Blobaum, A. L., & Marnett, L. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0613166 · Cited by 550
Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient
Laine, L. (2001) · Gastroenterology · doi:10.1053/gast.2001.21907 · Cited by 548
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Cannon, C. P., Curtis, S. P., FitzGerald, G. A., Krum, H., Kaur, A., Bolognese, J. A., Reicin, A. S., Bombardier, C., Weinblatt, M. E., van der Heijde, D., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69666-9 · Cited by 522
Self-citationCOX-2 and beyond: approaches to prostaglandin inhibition in human disease
FitzGerald, G. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1225 · Cited by 518
Self-citationCyclooxygenase-2—10 Years Later
Hinz, B., & Brune, K. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.367 · Cited by 518
Cancer and Inflammation: An Old Intuition with Rapidly Evolving New Concepts
Trinchieri, G. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075008 · Cited by 511
Platelets at work in primary hemostasis
Broos, K., Feys, H. B., De Meyer, S. F., Vanhoorelbeke, K., & Deckmyn, H. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.03.002 · Cited by 502
Farkouh, M. E., Kirshner, H., Harrington, R. A., Ruland, S., Verheugt, F. W., Schnitzer, T. J., Burmester, G. R., Mysler, E., Hochberg, M. C., Doherty, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16894-3 · Cited by 490
Resveratrol as an anticancer nutrient: molecular basis, open questions and promises
Signorelli, P., & Ghidoni, R. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.01.017 · Cited by 489
Cerebral ischemia and inflammation
Iadecola, C., & Alexander, M. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200102000-00014 · Cited by 466
Riendeau, D., Percival, M. D., Brideau, C., Charleson, S., Dubé, D., Ethier, D., Falgueyret, J.-P., Friesen, R. W., Gordon, R., Greig, G., et al. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38776-2 · Cited by 460
The development of COX2 inhibitors
Flower, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1034 · Cited by 459
Weber, A., Casini, A., Heine, A., Kuhn, D., Supuran, C. T., Scozzafava, A., & Klebe, G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030912m · Cited by 454
Martel-Pelletier, J., Lajeunesse, D., Reboul, P., & Pelletier, J.-P. (2003) · Annals of the Rheumatic Diseases · doi:10.1136/ard.62.6.501 · Cited by 439
Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review
Bacchi, S., Palumbo, P., Sponta, A., & Coppolino, M. F. (2012) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/187152312803476255 · Cited by 433
Charlier, C., & Michaux, C. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(03)00115-6 · Cited by 432
COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice
Egan, K. M., Lawson, J. A., Fries, S., Koller, B., Rader, D. J., Smyth, E. M., & FitzGerald, G. A. (2004) · Science · doi:10.1126/science.1103333 · Cited by 431
Self-citationClinical Pharmacokinetics and Pharmacodynamics of Celecoxib: A Selective Cyclo-Oxygenase-2 Inhibitor
Davies, N. M., McLachlan, A. J., Day, R. O., & Williams, K. M. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038030-00003 · Cited by 424
“[37] Amore recent study[14] has shown that at therapeutic doses celecoxib poorly inhibits thromboxaneA2-dependent platelet aggregation induced by arachidonic acid ex vivo.”
BackgroundMethodInfluentialInterplay between platelets and coagulation
Sang, Y., Roest, M., de Laat, B., de Groot, P. G., & Huskens, D. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100733 · Cited by 405
An overview of treatment approaches for chronic pain management
Hylands-White, N., Duarte, R. V., & Raphael, J. H. (2017) · Rheumatology International · doi:10.1007/s00296-016-3481-8 · Cited by 387
Shinmura, K., Tang, X.-L., Wang, Y., Xuan, Y.-T., Liu, S.-Q., Takano, H., Bhatnagar, A., & Bolli, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.18.10197 · Cited by 381
Augmented Expression of Cyclooxygenase-2 in Human Atherosclerotic Lesions
Schönbeck, U., Sukhova, G. K., Graber, P., Coulter, S., & Libby, P. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65230-3 · Cited by 379
Eikelboom, J. W., Hirsh, J., Spencer, F. A., Baglin, T. P., & Weitz, J. I. (2012) · Chest · doi:10.1378/chest.11-2293 · Cited by 379
Cyclooxygenase-1 and -2–Dependent Prostacyclin Formation in Patients With Atherosclerosis
Belton, O., Byrne, D., Kearney, D., Leahy, A., & Fitzgerald, D. J. (2000) · Circulation · doi:10.1161/01.cir.102.8.840 · Cited by 377
Kobayashi, T., Tahara, Y., Matsumoto, M., Iguchi, M., Sano, H., Murayama, T., Arai, H., Oida, H., Yurugi-Kobayashi, T., Yamashita, J. K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421446 · Cited by 373
Endothelium‐mediated control of vascular tone: COX‐1 and COX‐2 products
Félétou, M., Huang, Y., & Vanhoutte, P. M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01276.x · Cited by 372
Nonsteroidal anti-inflammatory drug gastropathy
Hawkey, C. J. (2000) · Gastroenterology · doi:10.1053/gast.2000.9561 · Cited by 371
Kozak, K. R., Crews, B. C., Morrow, J. D., Wang, L.-H., Ma, Y. H., Weinander, R., Jakobsson, P.-J., & Marnett, L. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206788200 · Cited by 368
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.764530 · Cited by 367
IL‐1β induces COX2, MMP‐1, ‐3 and ‐13, ADAMTS‐4, IL‐1β and IL‐6 in human tendon cells
Tsuzaki, M., Guyton, G., Garrett, W., Archambault, J. M., Herzog, W., Almekinders, L., Bynum, D., Yang, X., & Banes, A. J. (2003) · Journal of Orthopaedic Research · doi:10.1016/s0736-0266(02)00141-9 · Cited by 364
Patrono, C., Patrignani, P., & Rodríguez, L. A. G. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13418 · Cited by 364
Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease
Chenevard, R., Hürlimann, D., Béchir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R. E., Neidhart, M., et al. (2003) · Circulation · doi:10.1161/01.cir.0000051361.69808.3a · Cited by 358
van Hecken, A., Schwartz, J. I., Depré, M., de Lepeleire, I., Dallob, A., Tanaka, W., Wynants, K., Buntinx, A., Arnout, J., Wong, P. H., et al. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001005 · Cited by 354
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Konstam, M. A., Weir, M. R., Reicin, A., Shapiro, D., Sperling, R. S., Barr, E., & Gertz, B. J. (2001) · Circulation · doi:10.1161/hc4401.100078 · Cited by 352
Adverse Cardiovascular Effects of the Coxibs
Dogné, J.-M., Supuran, C. T., & Pratico, D. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0402059 · Cited by 344
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function
Cheng, Y. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27540 · Cited by 339
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study
Singh, G., Fort, J. G., Goldstein, J. L., Levy, R. A., Hanrahan, P. S., Bello, A. E., Andrade-Ortega, L., Wallemark, C., Agrawal, N. M., Eisen, G. M., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.054 · Cited by 335
Cyclooxygenase-2 and prostaglandins in articular tissues
Martel-Pelletier, J., Pelletier, J.-P., & Fahmi, H. (2003) · Seminars in Arthritis and Rheumatism · doi:10.1016/s0049-0172(03)00134-3 · Cited by 333
COX-2 Inhibitors and Cardiovascular Risk
Funk, C. D., & FitzGerald, G. A. (2007) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318157f72d · Cited by 330
Self-citationRay, W. A., Stein, C. M., Hall, K., Daugherty, J. R., & Griffin, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07370-1 · Cited by 326
Cyclo‐oxygenase‐2: pharmacology, physiology, biochemistry and relevance to NSAID therapy
Mitchell, J. A., & Warner, T. D. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702897 · Cited by 321
Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., & Fuchs, C. S. (2006) · Circulation · doi:10.1161/circulationaha.105.595793 · Cited by 319
COX-2: A Target for Colon Cancer Prevention
Marnett, L. J., & DuBois, R. N. (2002) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.42.082301.164620 · Cited by 313
Burla, B., Arita, M., Arita, M., Bendt, A. K., Cazenave-Gassiot, A., Dennis, E. A., Ekroos, K., Han, X., Ikeda, K., Liebisch, G., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.s087163 · Cited by 312
Aspirin resistance: definition, mechanisms and clinical read-outs
Patrono, C. (2003) · Journal of Thrombosis and Haemostasis · doi:10.1046/j.1538-7836.2003.00284.x · Cited by 299
Basic biology and clinical application of specific cyclooxygenase-2 inhibitors
Crofford, L. J., Lipsky, P. E., Brooks, P., Abramson, S. B., Simon, L. S., & Van De Putte, L. B. A. (2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200001)43:1<4::aid-anr2>3.0.co;2-v · Cited by 296
Celecoxib: A Review of its Use in Osteoarthritis, Rheumatoid Arthritis and Acute Pain
Clemett, D., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200059040-00017 · Cited by 287
Caughey, G. E., Cleland, L. G., Penglis, P. S., Gamble, J. R., & James, M. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2831 · Cited by 283
HALTER, F., TARNAWSKI, A. S., SCHMASSMANN, A., & PESKAR, B. M. (2001) · Gut · doi:10.1136/gut.49.3.443 · Cited by 285
Cyclooxygenase Inhibition and Cardiovascular Risk
Antman, E. M., DeMets, D., & Loscalzo, J. (2005) · Circulation · doi:10.1161/circulationaha.105.568451 · Cited by 282
Effects of Celecoxib and Naproxen on Renal Function in the Elderly
Whelton, A., Schulman, G., Wallemark, C., Drower, E. J., Isakson, P. C., Verburg, K. M., & Geis, G. S. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.10.1465 · Cited by 280
Mitchell, J. A., & Warner, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1929 · Cited by 279
Cyclooxygenase-2 Promotes Early Atherosclerotic Lesion Formation in LDL Receptor–Deficient Mice
Burleigh, M. E., Babaev, V. R., Oates, J. A., Harris, R. C., Gautam, S., Riendeau, D., Marnett, L. J., Morrow, J. D., Fazio, S., & Linton, M. F. (2002) · Circulation · doi:10.1161/01.cir.0000014927.74465.7f · Cited by 279
Do Nonsteroidal Anti-Inflammatory Drugs Affect Bone Healing? A Critical Analysis
Pountos, I., Georgouli, T., Calori, G. M., & Giannoudis, P. V. (2012) · The Scientific World Journal · doi:10.1100/2012/606404 · Cited by 274
Solomon, S. D., Pfeffer, M. A., McMurray, J. J. V., Fowler, R., Finn, P., Levin, B., Eagle, C., Hawk, E., Lechuga, M., Zauber, A. G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.636746 · Cited by 273
Stichtenoth, D. O., Thorén, S., Bian, H., Peters-Golden, M., Jakobsson, P.-J., & Crofford, L. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.469 · Cited by 269
Renal Effects of COX-2-Selective Inhibitors
Brater, D. C., Harris, C., Redfern, J. S., & Gertz, B. J. (2001) · American Journal of Nephrology · doi:10.1159/000046212 · Cited by 265
Bolli, R. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00414-5 · Cited by 258
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions
Undas, A., Brummel-Ziedins, K. E., & Mann, K. G. (2007) · Blood · doi:10.1182/blood-2006-01-010645 · Cited by 254
McAdam, B. F., Mardini, I. A., Habib, A., Burke, A., Lawson, J. A., Kapoor, S., & FitzGerald, G. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9523 · Cited by 253
Self-citationInflammation context in Alzheimer’s disease, a relationship intricate to define
Novoa, C., Salazar, P., Cisternas, P., Gherardelli, C., Vera-Salazar, R., Zolezzi, J. M., & Inestrosa, N. C. (2022) · Biological Research · doi:10.1186/s40659-022-00404-3 · Cited by 206
Schmidt, M., Lamberts, M., Olsen, A.-M. S., Fosbøll, E., Niessner, A., Tamargo, J., Rosano, G., Agewall, S., Kaski, J. C., Kjeldsen, K., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv505 · Cited by 164
Aljofan, M., & Ding, H. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.21986 · Cited by 58
Turtle, E. J., Dear, J. W., & Webb, D. J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12032 · Cited by 48
Liu, X., Thangavel, M., Sun, S. Q., Kaminsky, J., Mahautmr, P., Stitham, J., Hwa, J., & Ostrom, R. S. (2008) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-007-0196-0 · Cited by 35
Whelton, A. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.02.017 · Cited by 29
Metadata
- Authors
- McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-01-05
- Volume
- 96
- Issue
- 1
- Pages
- 272-277
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2020563114
- Cited by
- 1,305
- References
- 72
- FWCI
- 49.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.